NCT06643013View on ClinicalTrials.gov

Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease

NARecruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions

Cerebral Small Vessel Disease

Interventions

DRUG

XBD173

4 weeks treatment

Trial Locations (1)

Unknown

RECRUITING

Imperial Clinical Research Facility, London

All Listed Sponsors

lead

Imperial College London

OTHER